Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Hims & Hers Health (HIMS – Research ...

The success of an ongoing pilot programme offering RSV vaccination to newborn infants provides hope in tackling the ...

GlaxoSmithKline Pharmaceuticals reported a significant increase in net profit to Rs 229 crore for the third quarter ending ...

Astex Pharmaceuticals has been celebrating a very successful first 25 years following a visit from Science minister Patrick ...

The success of their audacious strategy paves ... says Professor Mark Sullivan, a former top executive at Gilead and GSK (GlaxoSmithKline). When Sullivan left big pharma in 2005 to found MDGH ...

GlaxoSmithKline has found a replacement for ... His time at Pfizer has coincided with the spectacular success of its BioNTech-partnered mRNA vaccine for COVID-19 – Comirnaty – and as GSK ...

GlaxoSmithKline Pharmaceuticals Limited is ... Cefspan (Cefixime - oral antibiotic) was relaunched with good success. Other branded generics launched during the year were Modvate 3 cream ...

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...